[Recent advances in the replacement therapy for Hemophilia].
作者信息
Hou P X, Yang R C
机构信息
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1052-1056. doi: 10.3760/cma.j.issn.0253-2727.2023.12.018.
Abstract
摘要
相似文献
1
[Recent advances in the replacement therapy for Hemophilia].[血友病替代疗法的最新进展]
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1052-1056. doi: 10.3760/cma.j.issn.0253-2727.2023.12.018.
2
Recent advances in the management of the child who has hemophilia.血友病患儿治疗的最新进展。
Hematol Oncol Clin North Am. 2004 Dec;18(6):1249-76, viii. doi: 10.1016/j.hoc.2004.06.016.
3
[Advances in the field of hemophilia therapy].[血友病治疗领域的进展]
Ned Tijdschr Geneeskd. 1968 Sep 7;112(36):1593-5.
4
[Recent advance in hemophilia therapy (2): gene and cell therapy for hemophilia].血友病治疗的最新进展（2）：血友病的基因治疗和细胞治疗
Rinsho Ketsueki. 2014 Aug;55(8):899-907.
5
[Hemophilia].[血友病]
Rinsho Ketsueki. 2013 Feb;54(2):189-97.
6
Status of gene transfer for hemophilia A and B.甲型和乙型血友病的基因转移现状。
Thromb Haemost. 1991 Jul 12;66(1):119-22.
7
Therapy for AHF and PTC hemophilia. I.急性失血性贫血和PTC血友病的治疗。一。
IMJ Ill Med J. 1970 May;137(5):518-21.
8
Gene therapy for hemophilia: the clot thickens.血友病的基因治疗：形势愈发复杂。
Hum Gene Ther. 2014 Nov;25(11):915-22. doi: 10.1089/hum.2014.2541.
9
A golden age for Haemophilia treatment?血友病治疗的黄金时代？
Haemophilia. 2018 Mar;24(2):175-176. doi: 10.1111/hae.13411.
10
[Experiences from the Hemophilia Clinic. II].[血友病诊所的经验。II]
Ned Tijdschr Geneeskd. 1968 Jul 27;112(30):1372-7.
引用本文的文献
1
[Chinese guidelines for emergency management of bleeding in hemophilia patients (2024)].《血友病患者出血的急诊处理中国指南（2024年）》
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):889-896. doi: 10.3760/cma.j.cn121090-20240809-00296.
本文引用的文献
1
Concizumab: First Approval.康西昔单抗：首次批准。
Drugs. 2023 Jul;83(11):1053-1059. doi: 10.1007/s40265-023-01912-6.
2
Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia.单剂量marstacimab在中国重度血友病患者中的安全性、耐受性、药代动力学和药效学
Haemophilia. 2023 Jul;29(4):1155-1159. doi: 10.1111/hae.14814. Epub 2023 Jun 20.
3
Efanesoctocog Alfa: First Approval.依非巴司他：美国首次批准
Drugs. 2023 May;83(7):633-638. doi: 10.1007/s40265-023-01866-9.
4
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.fitusiran预防治疗甲型或乙型血友病伴抑制剂患者的疗效和安全性（ATLAS-INH）：一项多中心、开放标签、随机3期试验。
Lancet. 2023 Apr 29;401(10386):1427-1437. doi: 10.1016/S0140-6736(23)00284-2. Epub 2023 Mar 29.
5
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.Fitusiran 预防疗法在无抑制剂的重型 A 型或 B 型血友病患者中的应用（ATLAS-A/B）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Haematol. 2023 May;10(5):e322-e332. doi: 10.1016/S2352-3026(23)00037-6. Epub 2023 Mar 29.
6
Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.依因子VIII预防严重A型血友病患者
N Engl J Med. 2023 Jan 26;388(4):310-318. doi: 10.1056/NEJMoa2209226.
7
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.依库珠单抗治疗中重度及轻度甲型血友病患者（HAVEN 6）：一项多中心、开放标签、单臂、3 期研究。
Lancet Haematol. 2023 Mar;10(3):e168-e177. doi: 10.1016/S2352-3026(22)00377-5. Epub 2023 Jan 27.
8
Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021.与依库珠单抗和延长半衰期的凝血因子 VIII 替代药物相关的出血和血栓不良事件：2021 年 EudraVigilance 数据。
J Thromb Haemost. 2023 Mar;21(3):546-552. doi: 10.1016/j.jtha.2023.01.010. Epub 2023 Jan 16.
9
Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results.抗组织因子途径抑制剂 marstacimab 在重度血友病患者中的长期安全性和疗效：II 期研究结果。
Br J Haematol. 2023 Jan;200(2):240-248. doi: 10.1111/bjh.18495. Epub 2022 Oct 11.
10
A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia.一项针对人组织因子途径抑制剂的马司他丁单抗的 1b/2 期临床研究在血友病中的应用。
Br J Haematol. 2023 Jan;200(2):229-239. doi: 10.1111/bjh.18420. Epub 2022 Aug 23.
Zotero 插件